Ralph DeBerardinis, M.D., Ph.D., is one of 17 cancer researchers across the country honored with the National Cancer Institute’s ‘2023 Outstanding Investigator Award,’ in recognition of his lab’s contributions toward breakthroughs in cancer research.
For the next 7 years, Dr. DeBerardinis will receive $600,000 annually, “allowing substantial time for funded investigators to take greater risks and be more adventurous in their research,” according to the NCI.
Dr. DeBerardinis is a Howard Hughes Medical Institute Investigator, Professor at Children’s Medical Center Research Institute at UT Southwestern (CRI), and Director of CRI’s Genetic and Metabolic Disease Program. The DeBerardinis lab studies how oncogenic control of metabolism supports tumor progression. Dr. DeBerardinis also studies pediatric inborn errors of metabolism, using metabolomics and genomics to identify new disease genes and deepen understanding of metabolism’s role in human health. One goal of the Outstanding Investigator Award will be to use inborn errors of metabolism as a window into mechanisms of cancer initiation.
Read more about Dr. DeBerardinis’ NCI award.
